Search Results - "Gniadecki, R"

The ecological approach to biologic drugs: survival of the fittest by Gniadecki, R.

“…Linked Article: Graier et al. Br J Dermatol 2021; 184:1094–1105…”
Get full text

How I learned to stop worrying about antidrug antibodies by Gniadecki, R.

“…Linked Article: Kimball et al. Br J Dermatol 2020; 182:180–189…”
Get full text

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis by Egeberg, A., Ottosen, M.B., Gniadecki, R., Broesby‐Olsen, S., Dam, T.N., Bryld, L.E., Rasmussen, M.K., Skov, L.

“…Summary Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐severe psoriasis are lacking. Objectives To examine safety,…”
Get full text

Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis by Mourad, A., Straube, S., Armijo‐Olivo, S., Gniadecki, R.

“…Summary Background Long‐term therapy for psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect…”
Get full text

Next-generation antipsoriatic drugs: small molecules join by Gniadecki, R.

“…Linked Article: Paul, et al. Br J Dermatol 2015; 173: 1387–99…”
Get full text

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris by Gniadecki, R., Bang, B., Bryld, L.E., Iversen, L., Lasthein, S., Skov, L.

“…Summary Background Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long‐term therapeutic performance…”
Get full text

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis by Wu, J.J., Kavanaugh, A., Lebwohl, M.G., Gniadecki, R., Merola, J.F.

“…Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities in addition to the characteristic skin lesions. Metabolic syndrome…”
Get full text

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris by Gniadecki, R., Kragballe, K., Dam, T.N., Skov, L.

“…Summary Background  Adherence to treatment is an indicator of treatment success. Long‐term data on adherence to biologic treatment in psoriasis are lacking…”
Get full text

European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1 by Knobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F., Cho, A., French, L.E., Gennery, A.R., Gniadecki, R., Gollnick, H.P.M., Guenova, E., Jaksch, P., Jantschitsch, C., Klemke, C., Ludvigsson, J., Papadavid, E., Scarisbrick, J., Schwarz, T., Stadler, R., Wolf, P., Zic, J., Zouboulis, C., Zuckermann, A., Greinix, H.

“…Background Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma published in…”
Get full text

Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort by Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L.E., Lasthein, S., Lindhardsen, J., Kristensen, S.L., Torp-Pedersen, C., Hansen, P.R.

“…Background Psoriasis is a common disease and is associated with cardiovascular diseases. Systemic anti‐inflammatory drugs may reduce risk of cardiovascular…”
Get full text

Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study by Gniadecki, R., Bang, B., Sand, C.

Get full text

Predicting the long‐term outcomes of biologics in patients with psoriasis using machine learning by Emam, S., Du, A.X., Surmanowicz, P., Thomsen, S.F., Greiner, R., Gniadecki, R.

Get full text

Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a Danish real‐world cohort study by Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T. N., Torp‐Pedersen, C., Hansen, P. R.

“…Objectives Psoriasis is a chronic inflammatory disorder associated with cardiovascular morbidity and mortality. Systemic anti‐inflammatory drugs, including…”
Get full text

An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis by Eyerich, K., Krueger, J., Stahle, M., Schakel, K., Conrad, C., Armstrong, A., Gniadecki, R., Puig, L., Scoble, T., Williams, N.

Get full text

A randomized, double‐blind, placebo‐controlled, dose‐escalation first‐in‐man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis by Omland, S.H., Habicht, A., Damsbo, P., Wilms, J., Johansen, B., Gniadecki, R.

“…Background Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was…”
Get full text

MicroRNAs in the pathogenesis of malignant melanoma by Glud, M., Gniadecki, R.

“…Cutaneous malignant melanoma is the most aggressive and lethal form of skin cancer. Over the past decades, its incidence has been increasing by 3–8% per year…”
Get full text

Transcriptomic changes during stage progression of mycosis fungoides by Xiao, M.Z.X., Hennessey, D., Iyer, A., O’Keefe, S., Zhang, F., Sivanand, A., Gniadecki, R.

“…Summary Background Mycosis fungoides (MF) is the most common cutaneous T‐cell lymphoma, which in the early patch/plaque stages runs an indolent course…”
Get full text

Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real‐world evidence study by Schwensen, J.F.B., Nielsen, V.W., Nissen, C.V., Sand, C., Gniadecki, R., Thomsen, S.F.

Get full text

Ubiquitin‐specific peptidase 2 as a potential link between microRNA‐125b and psoriasis by Wei, T., Folkersen, L., Biskup, E., Xu, N., Manfe, V., Niazi, O., Gniadecki, R.

“…Summary Background The extensive involvement of microRNA (miRNA) in the pathophysiology of psoriasis is well documented. However, in order for this information…”
Get full text

The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology by Liszewski, W., Gniadecki, R.

“…Cytokines are small, secreted proteins that are essential for promoting and maintaining a normal immune response. Upregulation of cytokines frequently occurs…”
Get full text